Denmark reported on Saturday that after receiving the AstraZeneca Covid-19 vaccine, two people suffered cerebral haemorrhage, one of whom died. The Danish Medicines Agency said it was looking to see if the disease was a possible side effect.
A spokesman for the capital region of Denmark confirmed the death, and the Danish news agency Ritzau reported that the other person, a civil servant in her thirties, was seriously ill.
Millions of people in dozens of countries have received the AstraZeneca Covid-19 vaccine with few reports of side effects. However, the European Medicines Agency, the continent’s top medicines agency, carried out a review after several countries stopped using the vaccine. On Thursday, the agency said it thought the vaccine was safe, although it would continue to look out for links to blood disorders. It was determined that any threat would be very minor and that the gunfire would prevent far more deaths than they could cause.
Recent blood clots and abnormal bleeding in a small number of vaccine recipients in European countries raised safety issues and resulted in suspensions. This resulted in a disruptive pause in vaccination campaigns this week, although some European countries entered a third wave of infections.
“At the moment we are investigating whether this is exactly the same clinical picture with multiple blood clots, low platelet counts and bleeding,” said Tanja Erichsen, director of the Danish Medicines Agency, in a radio interview with the Danish national broadcaster DR.
“We prioritize reports of suspected serious side effects like these and investigate them thoroughly to determine whether there is a possible link to the vaccine,” Ms. Erichsen said on Twitter on Saturday. “We are in the process of dealing with the two specific cases.”
This is the second death in Denmark after a person received the AstraZeneca vaccine. Norway is investigating the deaths of two people who received the vaccine.
Denmark has suspended the use of AstraZeneca until Thursday, despite assurances from the European Medicines Agency. Other Scandinavian countries and Finland have made similar decisions. However, some European countries, including France and Germany, have resumed recording.
Part of the continued caution is due to preliminary results from medical experts in Norway and Germany, which suggest a possible link between the vaccine and the extremely rare blood disorders. The German experts said the sinus or cerebral vein thrombosis, which Germans suffered 13 days after receiving the vaccine, was caused by an immune system reaction they believe may be related to the shot. They did not publish detailed data, but planned to present their results to The Lancet.
AstraZeneca didn’t immediately comment on the claims on Friday.
Dr. James Bussel, an expert in platelet disorders and professor emeritus at Weill Cornell Medicine, said the occurrence of abnormal clotting and low platelets in people under the age of 50 was unusual. He found that researchers in Europe had identified antibodies produced by the immune system – possibly in a highly unusual response to the vaccine – that may have activated platelets and triggered a cascade of abnormal clotting and bleeding.
Researchers in Germany and Norway will continue their research. In Germany, where the vaccine is being re-administered, doctors are now warning anyone who receives an AstraZeneca shot to see a doctor immediately if they have a headache, dizziness, or blurred vision more than three days later. They said the problems could very likely be addressed if identified in time.
